Name
RF2-03: Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial Commentary by: Joseph Sparano, MD, FACP
Date & Time
Monday, December 1, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL